SIDMAP Technology Used to Characterize Novel Drug for Type 2 Diabetes

Published: Jul 21, 2010

LOS ANGELES--(BUSINESS WIRE)--SiDMAP, LLC (, a privately held life-science company that provides metabolomics research services to the pharmaceutical and biotechnology industries and the academic biomedical research community worldwide, announced today results of a study conducted in collaboration with scientists at Roche (Nutley, NJ), a leading pharmaceutical company, on a novel Roche drug for Type 2 diabetes.

Back to news